<DOC>
	<DOCNO>NCT01594073</DOCNO>
	<brief_summary>Implantable cardioverter-defibrillator ( ICD ) therapy reduces mortality patient chronic heart failure reduce leave ventricular ejection fraction ( LVEF ) &lt; 36 % . Nevertheless , patient selection ICD therapy base LVEF NYHA functional class alone seem low specificity sensitivity : In 100 patient treat , SCD-HeFT study prevent 7 death 5 year . Therefore 93 patient risk adverse effect , operation risk , infection , pneumothorax , lead dislocation , inadequate icd therapy . On hand , patient advance end stage heart failure might rather die progressive heart failure death thus benefit ICD therapy . It therefore seem appropriate necessary improve individualize risk stratification patient . The aim study evaluate multiple cardiac biomarkers model predict ventricular arrhythmia patient ICD therapy .</brief_summary>
	<brief_title>Evaluation Novel Biomarkers Improve Risk Stratification Patient Selection Implantable Cardioverter-defibrillator ( ICD ) Therapy</brief_title>
	<detailed_description>Patients get ICD Dept . Cardiovascular Medicine Hannover Medical School recruit next 2 year . Blood sample patient obtain inclusion 6 month follow-up . Patients followed-up 1-2 year inclusion .</detailed_description>
	<mesh_term>Death</mesh_term>
	<criteria>Patient meeting current indication primary secondary prophylactic ICD/CRTD therapy age 18 year old Patient unwilling participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>implantable defibrillator</keyword>
	<keyword>ventricular arrhythmia</keyword>
	<keyword>cardiac death</keyword>
</DOC>